logo-loader
viewMotif Bio PLC

Motif Bio in a strong position to build pipeline says chief

Graham Lumsden, chief executive of Motif Bio PLC (LON:MTFB) says the company “accomplished a lot” last year, leaving the company “in a very strong position now”.

So much so, the company is in the market for new antibiotics to add to its pipeline after making significant progress with iclaprim, its next-generation drug targeting hard-to-treat infections.

Lumsden also says the company should be ready to list on the Nasdaq market this year, with Motif already in negotiations with banks, and he adds that there are signs that markets are “starting to become a little bit more sensible” with the biotech index up around 26% so far this year.

Quick facts: Motif Bio PLC

Price: 0.068 GBX

AIM:MTFB
Market: AIM
Market Cap: £330.04 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Nextleaf secures extraction deal for 15 metric tons of cannabis

NextLeaf Solutions (CSE: OIL) CEO Paul Pedersen joined Steve Darling from Proactive Vancouver to discuss the company agreeing to a deal with an Ontario based company to provide extraction for their biomass. Pedersen telling Proactive about the potential revenue from this deal and also what...

2 hours, 15 minutes ago

2 min read